Details for Patent: 11,273,158
✉ Email this page to a colleague
Which drugs does patent 11,273,158 protect, and when does it expire?
Patent 11,273,158 protects ARISTADA and ARISTADA INITIO KIT and is included in two NDAs.
This patent has ten patent family members in six countries.
Summary for Patent: 11,273,158
| Title: | Aripiprazole dosing strategy |
| Abstract: | The present invention relates to methods of treating schizophrenia using a combination of aripiprazole, aripiprazole lauroxil, and a nanoparticle dispersion of aripiprazole lauroxil. |
| Inventor(s): | Lisa L. von Moltke, Peter J. Weiden, Marjie L. Hard |
| Assignee: | Alkermes Pharma Ireland Ltd |
| Application Number: | US16/291,768 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 11,273,158
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alkermes Inc | ARISTADA | aripiprazole lauroxil | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207533-001 | Oct 5, 2015 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF SCHIZOPHRENIA | ⤷ Start Trial | ||||
| Alkermes Inc | ARISTADA | aripiprazole lauroxil | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207533-002 | Oct 5, 2015 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF SCHIZOPHRENIA | ⤷ Start Trial | ||||
| Alkermes Inc | ARISTADA | aripiprazole lauroxil | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207533-003 | Oct 5, 2015 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF SCHIZOPHRENIA | ⤷ Start Trial | ||||
| Alkermes Inc | ARISTADA | aripiprazole lauroxil | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 207533-004 | Jun 5, 2017 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF SCHIZOPHRENIA | ⤷ Start Trial | ||||
| Alkermes Inc | ARISTADA INITIO KIT | aripiprazole lauroxil | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 209830-001 | Jun 29, 2018 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF SCHIZOPHRENIA | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,273,158
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2019230014 | ⤷ Start Trial | |||
| Canada | 3092335 | ⤷ Start Trial | |||
| China | 112423754 | ⤷ Start Trial | |||
| European Patent Office | 3761983 | ⤷ Start Trial | |||
| Japan | 2021516241 | ⤷ Start Trial | |||
| Japan | 2024014928 | ⤷ Start Trial | |||
| Japan | 2025096361 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
